**Supplementary Table 4. Network meta-analysis results for primary and secondary prophylaxis of variceal bleeding and all-cause mortality according to geographical region**

|  |  |  |  |
| --- | --- | --- | --- |
| **Bleeding (primary + secondary prophylaxis)** | |  |  |
| *Asia* (10 studies) | |  |  |
| Carvedilol  1.49 (0.45, 4.99) Nadolol  0.49 (0.11, 1.68) 0.33 (0.07, 1.14) | | Propranolol |  |
| 0.56 (0.16, 1.92) 0.38 (0.11, 1.23) | | 1.16 (0.57, 2.96) | Placebo |
| *Non-Asia* (19 studies) | |  |  |
| Carvedilol 0.00 (0.00, 0.74) | Nadolol |  |  |
| 0.00 (0.00, 0.34) | 0.46 (0.13, 1.45) | Propranolol |  |
| 0.00 (0.00, 0.15) | **0.20 (0.06, 0.57)** | **0.42 (0.27, 0.64)** | Placebo |
| **All-cause mortality** |  |  |  |
| *Asia* (9 studies)  Carvedilol  0.76 (0.27, 1.93) |  |  |  |
| Nadolol |  |  |
| **0.32 (0.09, 0.94)** | 0.42 (0.11, 1.41) | Propranolol |  |
| **0.28 (0.11, 0.65)** | **0.38 (0.13, 0.98)** | 0.90 (0.40, 2.14) | Placebo |
| *Non-Asia* (16 studies) | |  |  |
| Carvedilol 0.52 (0.12, 2.13) | Nadolol |  |  |
| 0.39 (0.10, 1.27) | 0.74 (0.33, 1.64) | Propranolol |  |
| **0.29 (0.08, 0.94)** | 0.56 (0.26, 1.14) | 0.75 (0.53, 1.05) | Placebo |

Data are presented as pooled relative risk (95% credible interval). Bold text indicates statistically significant value.